Overall, the combination of pembrolizumab and chemotherapy showcased a favorable combination of effectiveness and safety for patients diagnosed with PD-L1-positive, HER2-negative GC or GEJC [30]. This evidence concerns the gene ERBB2 and gastric cancer.